GlycoNex and PrecisemAb Join Hands to Develop New Anti-Glycan Antibodies for Cancer Therapy
Shots:
- GlycoNex & PrecisemAb have entered into a technology licensing agreement for the development of novel anti-glycan antibody drugs to elevate Ab specificity, minimize drug side effects & improve treatment outcomes for various solid tumors
- Under the agreement, GlycoNex will license PrecisemAb's Universal Antibody Lock (UAL) technology, which activates antibodies only in the presence of tumor proteases. This, combined with GlycoNex's anti-glycan Ab platform, aims to improve therapeutic precision, safety and tolerability, minimizing side effects by preventing off-target binding
- Additionally, the company is advancing GNX-102 which targets tumor-associated glycans plus depicted favorable results in clinical evaluations
Ref: PRNewswire | Image: GlycoNex
Related News:- Amgen's Lumakras (sotorasib) Receives the US FDA's Approval as the First KRAS Blocking Cancer Therapy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
